Cerebain Biotech Today Announced It Plans to Seek FDA Approval

DALLAS–(BUSINESS WIRE)–Cerebain Biotech (OTCQB: CBBT) today announced that the company intends
to seek FDA approval in conjunction with the development and testing of
its medical device for the treatment of Alzheimer’s and Dementia.
The Company has reached a decisive point in their research and is
planning to commence development of the device. As previously expressed,
the Company has three options for implantable devices with a bias
towards having them as non-invasive as possible. It is theorized that if
a patient’s response to the omentum stimulation is successful, the
clinical facility should be able to perform various tests for the
purpose of setting “markers” for the patient and then perform the
standardized cognitive testing for Alzheimer’s patients.
Eric Clemons, president and CEO of Cerebain, stated, “It is vital we
identify an individual to create our surgical manual for device
implantation who has a broad perspective on the Global Healthcare System
and its challenges. Their experience must encompass public, private and
academic settings, with proficiencies in public health, statistics and
clinical research.” Mr. Clemons further stated, “We have entered into
discussions with a prominent Medical Doctor we deem demonstrates these
stringent guidelines.”
Scott Walker, former Governor of Wisconsin, has initiated discussions
pertaining to the representation of the Company in Poland for the
purpose of Clinical Testing of the Company’s Medical Device for the
treatment of Alzheimer’s disease utilizing the Omentum. The purpose of
these discussions is to determine and finalize any required local
approvals and establish essential partnerships with Doctors and Medical
Facilities necessary for this testing.
The Company has engaged the services of Hamilton Advisors of Great
Falls, VA, to support business development goals that will help the
company accelerate its research programs, with an emphasis on receiving
FDA approval.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device
company focused on the creation and clinical development of a minimally
invasive implantable device and a synthetic drug solution. The device
leverages the clinically observable, positive impact that omentum
stimulation has on cognitive function as related to dementias, and in
particular, Alzheimer’s disease. The corporate vision is based on these
positive clinical observations.
Forward Looking Statements
This news release contains certain “forward- looking statements.”
Forward-looking statements are based on current expectations and
assumptions and are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified, and many of which are beyond
the Company’s control. The forward-looking statements are also
identified through the use of words “believe,” enable,” “may,” “will,”
“could,” “intends,” “estimate,” “anticipate,” “plan,” “predict”
“probable,” “potential,” “possible,” “should,” “continue,” and other
words of similar meaning. Actual results could differ materially from
these forward-looking statements as a result of a number of risk factors
detailed in the Company’s reports filed with OTC Markets. Given these
risks and uncertainties, investors are cautioned not to place undue
reliance on such forward-looking statements and no assurances can be
given that such statements will be achieved.